Abstract
We reported an association between SARS‐CoV‐2 infection and Guillain–Barre syndrome (GBS). From 37 patients with GBS, previous SARS‐CoV‐2 clinical clues, including fever, cough, and diarrhea, were recorded in 18 patients. Among them, SARS‐CoV‐2 IgG was detected in seven patients, considered confirmed as cases. SARS‐CoV‐2 PCR was positive in just one patient. Although we found no increase in patient recruitment during the pandemic compared to previous years, our study indicated that SARS‐CoV‐2 is associated with poorer outcomes regarding GBS disability scale and hospital stay.
Keywords: Guillain–Barre syndrome, pediatric, SARS‐CoV‐2
Short abstract
Although the rate of Guillain–Barre syndrome in children associated with SARS‐CoV‐2 was the same as previous years, it would be related to more hospital stay and serious complications that is necessary for pediatric neurologists to mention.
1. INTRODUCTION
According to previous reports of neurologic manifestations of coronaviruses, it was expected that we would find these neurological disorders in the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), including headache, seizures, cerebrovascular disorders, and Guillain–Barre syndrome (GBS). 1 , 2
Guillain–Barre syndrome is an immune‐mediated peripheral neuropathy, typically characterized by rapidly progressive bilateral and often symmetrical loss of sensory and motor functions of the limbs. It might also involve respiratory or cranial nerve‐innervated muscles. 3 GBS is usually preceded by an infection that often has been caused by Campylobacter jejuni or other bacterial or viral agents. 4 GBS has been associated with respiratory viral pathogens such as human coronaviruses 5 ; therefore, an outbreak of some viral infections may lead to increased admission of GBS patients.
Based on clinical and electrophysiologic studies, GBS is divided into several subtypes, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), two axonal forms of GBS including acute motor‐sensory axonal neuropathy (AMSAN), and acute motor axonal neuropathy (AMAN) and Miller Fisher syndrome (MFS). 6 Preceding infections may result in special clinical and electrophysiological subtypes of GBS. 7
There are some neurologic complications in children, associated with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A 6‐year‐old male patient had been reported with a rapid progression axonal GBS and positive SARS‐CoV‐2 infection. 8 A 9‐year‐old boy with reported with positive SARS‐CoV‐2 infection and self‐recovered Guillain–Barré syndrome without immunotherapy. 9
During the SARS‐CoV‐2 pandemic, we assumed that the incidence of GBS had increased, and the subtypes may change; therefore, we set up a prospective study for neurological manifestations of SARS‐CoV‐2 infections in the Children's Medical Center (CMC), Tehran, which is one of the largest referral pediatric centers in Iran. We reported the clinical finding, electrophysiological subtype, and disease course of all GBS patients during the 17‐month period of study.
2. MATERIALS AND METHODS
This prospective study was performed in Children Medical Center, Tehran, Iran, from March 2020 to August 2021. All patients' parents had assigned the consent form. This study was approved by the Ethics Committee of Tehran University of Medical Sciences, (Ethic code: IR.TUMS.VCR.REC. 1399.326).
All admitted children that fulfill the diagnostic criteria for GBS (National Institute of Neurological Disorders and Stroke) enrolled during the study period. 10 Exclusion criteria for this study were as follows: other neurological diseases, which could affect brain function, sequelae neurologic deficits that could affect the evaluation of GBS severity.
Demographic data, associated symptoms, GBS severity according to disability scale 1 , 11 on admission and discharge time, clinical and electrophysiologic features, SARS‐CoV‐2 status, and other important data were recorded in a structured checklist. Disability Scale in GBS is defined as the following: 0. Healthy; 1. Minor signs or symptoms of neuropathy but capable of manual work; 2. Able to walk without the support of a stick but incapable of manual work; 3. Able to walk with a stick, appliance, or support; 4. Confined to bed or chairbound; and 5. Requiring assisted ventilation. 6 Death. 11
All patients with GBS underwent standard treatment by IVIG as indicated. Data analyzed with suitable statistical methods.
Clinical suspicion of SARS‐CoV‐2 infection, laboratory, radiological, and serological evidence recorded for all patients. Reverse‐transcription polymerase chain reaction (RT‐PCR) of nasopharyngeal swab specimen and serum antibodies (IgM and IgG) was requested for all patients. Patients with positive SARS‐CoV‐2 PCR or antibodies defined as confirmed SARS‐CoV‐2 cases and those with clinical symptoms including fever, diarrhea, and upper respiratory complaints or imaging finding in favor of SARS‐CoV‐2 or contact with confirmed SARS‐CoV‐2 cases before neurologic signs considered as probable SARS‐CoV‐2 cases. 12
3. RESULTS
Of 37 patients with GBS, 28 were male and 9 were female. The mean age was 8.19 ± 3.49 years, ranging from 2.5 to 15 years. The frequency of previous SARS‐CoV‐2 clinical clues, including fever, cough, and diarrhea, was 48%. SARS‐CoV‐2 PCR or antibodies were detected in 7 patients (19%), considered as confirmed cases. Among them, SARS‐CoV‐2 PCR was positive in just 1 patient. The overall frequency of confirmed plus probable SARS‐CoV‐2 in GBS patients was 60% (N = 22). The median time from the onset of infection to neurological symptoms was 11.25 ± 8.44 days (ranging from 2 to 30 days). Demographic data and clinical findings according to SARS‐Cov‐2 infection status are noted in Table 1.
TABLE 1.
Frequency of demographic and clinical findings according to SARS‐Cov‐2 infection status.
| SARS‐CoV‐2 negative (N = 15) | Confirmed SARS‐CoV‐2 (N = 7) | Confirmed and Probable SARS‐CoV‐2 (N = 22) | Total (N = 37) | |
|---|---|---|---|---|
| Sex | ||||
| Male | 12 (80%) | 5 (71%) | 16 (72) | 28 (76%) |
| Female | 3 (20%) | 2 (29%) | 6 (28%) | 9 (24%) |
| Previous suspected symptoms a | ||||
| Fever | 0 | 2 (28%) | 8 (36%) | 8 (22%) |
| Diarrhea | 0 | 1 (14%) | 6 (27%) | 6 (16%) |
| URI | 0 | 2 (28%) | 10 (45%) | 10 (27%) |
| Disability scale on admission | ||||
| 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 |
| 2 | 5 (33%) | 0 | 6 (27%) | 11 (30%) |
| 3 | 7 (47%) | 3 (43%) | 9 (41%) | 16 (43%) |
| 4 | 3 (20%) | 3 (43%) | 5 (23%) | 8 (22%) |
| 5 | 0 | 1 (14%) | 2 (9%) | 2 (5%) |
| 6 | 0 | 0 | 0 | 0 |
| Electrodiagnostic findings | ||||
| AIDP | 4 (26%) | 2 (29%) | 8 (36%) | 12 (32%) |
| AMAN | 10 (67%) | 5 (71%) | 14 (64%) | 24 (65%) |
| AMSAN | 1 (17%) | 0 | 0 | 1 (3%) |
| Disability scale at discharge | ||||
| 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 1 (4%) | 1 (3%) |
| 2 | 5 (33%) | 1 (14%) | 6 (27%) | 11 (30%) |
| 3 | 7 (47%) | 4 (57%) | 13 (60%) | 20 (54%) |
| 4 | 3 (20%) | 2 (29%) | 2 (9%) | 5 (13%) |
| 5 | 0 | 0 | 0 | 0 |
| 6 | 0 | 0 | 0 | 0 |
Note: Two confirmed patients had no symptoms.
Please notice that the number of symptoms does not refer to number of patients, necessarily, as one patient may have more than one symptom.
All patients underwent electrophysiological examination, and acute axonal type motor polyneuropathy was the most prevalent type in both SARS‐CoV‐2‐positive and SARS‐CoV‐2‐negative patients. The second frequent type was acute segmental demyelinating motor polyradiculoneuropathy. The disability scale in most of the patients on admission and on discharge was 3 in 43.2% and 54.1%, respectively.
Acute motor axonal neuropathy was the most frequent subtype of GBS in all our patients (65%), apart from SARS‐CoV‐2 infection status. The second frequent subtype was AIDP (32%), and the AMSAN subtype was detected in just one SARS‐CoV‐2 infection‐negative patient. These findings were not significantly different between SARS‐CoV‐2 infection positive and negative cases (p value: 0.42).
Guillain‐Barré syndrome disability scale 4 ≤ out of 6 at presentation in confirmed patients with SARS‐CoV‐2 infection was 57%, in comparison with 20% in SARS‐CoV‐2 infection‐negative patients, which was statistically significant (p value: 0.02). One patient was an obese 8‐year‐old boy with a history of fever 14 days before weakness onset and SARS‐CoV‐2 IgG was positive. GBS disability scale (DS) on admission was 5 out of 6. During 24 h of lower limb weakness, the ascending process involved the respiratory system and he was intubated for about 2 weeks and then underwent tracheostomy for 2 months later. Another patient was a 15‐year‐old girl with a history of lupus erythematous and upper respiratory infection symptoms around 3 weeks before weakness; however, SARS‐CoV‐2 antibodies or PCR were negative. She had ascending weakness and diplopia, after 1 week of the disease, she underwent intubation for 3 weeks and then tracheostomy for 1.5 months later. Both patients had refractory hypertension and tachycardia. Treatment was challenging, and they received IVIG. After 4 weeks of treatment, they received high dose of methylprednisolone, due to poor response to IVIG. Electrophysiology study was in favor of acute motor axonal neuropathy in both of them. They had the longest hospital admission time which was around 90 and 60 days, respectively.
The mean of hospital admission time, among confirmed SARS‐CoV‐2 infection patients, was 19.7 days, and among confirmed plus probable SARS‐CoV‐2 infection was 11.8 days. These amounts are significantly higher than 5.5 days in SARS‐CoV‐2 infection‐negative patients (p value < 0.05). Hospital stay was longer in around 8‐year‐old patients, with a mean of 20 days. Acute axonal type motor polyneuropathy was associated with the longest admission time (mean 11.78 ± 20.32 days, ranging from 4 to 89 days). This variable was longer in SARS‐CoV‐2 positive in comparison with those with negative SARS‐CoV‐2.
4. DISCUSSION
In a study of 81 patients, most patients were diagnosed with AIDP. Three of the patients died at the end of the first month. Three patients had recurrent GBS. Seventy‐four patients received IVIG while eight patients were treated with plasma exchange after IVIG because of ineffective treatment. Seven of the patients were followed without treatment. 4
Among 49 children with GBS, rapid progression to maximum paralysis was seen in the male gender, while the older age group in pediatrics is expected to endure residual paralysis at 60 days after disease onset. Patients in colder seasons were more likely to have residual paralysis too, compared to warmer seasons. 5
Among 30 children with GBS diagnosis, in Iran, 12 participants were diagnosed with acute inflammatory demyelinating polyradiculoneuropathy and 18 patients were diagnosed with acute motor axonal neuropathy. 6 GBS is usually preceded by an infectious viral or bacterial process. 4 Here, we investigated the association between SARS‐CoV‐2 and GBS in children. Previously, we performed a study from March 2014 to 2017, in a tertiary children's hospital that enrolled 69 children with GBS. The prevalence of GBS in the new study, during the SARS‐CoV‐2 pandemic, is higher; however, this difference is not statistically valuable.
The male to female ratio in our study was 3.1, and among confirmed cases, this ratio was 2.5. in a study by M. Ashrafi et al. 13 in 2008, in Iran, this ratio was 1.05, which may reflect the higher male involvement during SARS‐CoV‐2 pandemic.
The frequency (60%) of a preceding SARS‐CoV‐2 infection track(confirmed plus probable cases) in our study population was higher than estimates in a multicenter study by Luijten LWG, et al. 14 on adults with GBS, which was 22%. This may reflect the higher incidence of SARS‐CoV‐2 infection in Iran, during that time, which was about 1 million in 80 million population according to an official report of the ministry of health and medical education of Iran.
Disability scale 4 ≤ of 6 and at presentation in confirmed patients with SARS‐CoV‐2 infection was 57%, in comparison with 20% in SARS‐CoV‐2 infection‐negative patients, which was statistically significant. Just as, we had one intubated patient in confirmed and one in probable cases. These findings along with the longest hospital admission time in SARS‐CoV‐2 infection patients may reflect a poorer prognosis among SARS‐CoV‐2 infection patients.
Acute motor axonal neuropathy was the most frequent subtype of GBS in all our patients (65%), apart from SARS‐CoV‐2 infection status. This finding, is concordant with a study of M. Ashrafi et al. 15 in Iran and different from studies of other countries, with AIDP predominance. 16 The second frequent subtype was AIDP (32%) and AMSAN was detected in just one SARS‐CoV‐2 infection‐negative patient. These findings were not significantly different between SARS‐CoV‐2 infection positive and negative cases.
5. CONCLUSION
Consistent with previous studies, we found no increase in GBS patient recruitment during the pandemic compared to previous years; however, our study indicated that SARS‐CoV‐2 is associated with poorer outcomes. Since our study was performed with 37 patients, we could not determine the causative relationship. Therefore, we recommend studies with a larger sample size to determine whether there is a causative association or not.
AUTHOR CONTRIBUTIONS
M.A., M.H.: Conceptualization, Methodology, Software. E.P., M.H., A.R.T.: Data curation, Writing‐ Original draft preparation. RSB, M.M, G.R.Z., M.G.A., E.H.E.M., R.H.: Visualization, Investigation. M.A., S.M., M.H.: Supervision. S.M.M.H., H.G., Z.R.: Software, Validation. E.P., M.H.: Writing‐ Reviewing and Editing. All authors read and approved the final manuscript.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.
ETHICAL APPROVAL
Ethics approval obtained from the Tehran University of Medical Sciences (approval number: IR.TUMS.VCR.REC.1399.326). Written informed consent was obtained from the patients' parents for inclusion in the study, in accordance with the ethical guidelines by the ethics committee of Tehran University of Medical Sciences.
CONSENT
Written informed consent was obtained from the patients' parents to publish this report in accordance with the journal's patient consent policy.
6. ACKNOWLEDGMENT
None.
Pourbakhtyaran E, Heidari M, Akbari MG, et al. Childhood Guillain–Barre syndrome in the SARS‐CoV‐2 era: Is there any causative relation? Clin Case Rep. 2022;10:e06772. doi: 10.1002/ccr3.6772
Elham Pourbakhtyaran and Morteza Heidari have an equal contribution as the first author.
DATA AVAILABILITY STATEMENT
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
REFERENCES
- 1. Ashrafi MR, Azizimalamiri R, Badv RS, et al. Coronavirus, its neurologic manifestations, and complications. Iran J Pediatr. 2020;30(2):1‐4. [Google Scholar]
- 2. Ashrafi MR, Mohammadi M, Zamani G, et al. We need well‐designed multicenter studies to investigate neurologic manifestations of coronavirus disease 2019. Curr J Neurol. 2020;19(3):150‐151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain‐Barré syndrome. Lancet Neurol. 2007;6(7):589‐594. [DOI] [PubMed] [Google Scholar]
- 4. González‐Suárez I, Sanz‐Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain‐Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol. 2013;13:2‐7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Robinson CP, Busl KM. Neurologic manifestations of severe respiratory viral contagions. Crit Care Explor. 2020;2(4):e0107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Hung PL, Chang WN, Huang LT, et al. A clinical and electrophysiologic survey of childhood Guillain‐ Barré syndrome. Pediatr Neurol. 2004;30(2):86‐91. [DOI] [PubMed] [Google Scholar]
- 7. Jacobs BC, Van Doorn PA, Schmitz PIM, et al. Campylobacter jejuni infections and anti‐GM1 antibodies in Guillain‐ Barre syndrome. Ann Neurol. 1996;40(2):181‐187. [DOI] [PubMed] [Google Scholar]
- 8. Akçay N, Menentoğlu ME, Bektaş G, Şevketoğlu E. Axonal Guillain‐Barre syndrome associated with SARS‐CoV‐2 infection in a child. J Med Virol. 2021;93(9):5599‐5602. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Kanou S, Wardeh L, Govindarajan S, Macnay K. Guillain‐Barre syndrome (GBS) associated with COVID‐19 infection that resolved without treatment in a child. BMJ Case Rep. 2022;15(3):1‐4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain‐Barré syndrome. Ann Neurol. 1990;27(1S):S21‐S24. [DOI] [PubMed] [Google Scholar]
- 11. Hughes RA, Newsom‐Davis JM, Perkin GDPJ. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2(8093):750‐753. [DOI] [PubMed] [Google Scholar]
- 12. European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID‐19) as of 29 M 2020. A 1 S 2020. https://www.ecdc.europa.eu.en/covid‐19/surveillance/case‐definition. No Title. [Google Scholar]
- 13. Ashrafi MR, Sagheb S, Mohammadi M, Vakili A, Nasirian A, Zamani GR. Clinical short term outcome of Guillain‐Barré syndrome in children. Iran J Pediatr. 2008;18(1):11‐19. [Google Scholar]
- 14. Luijten LWG, Leonhard SE, van der Eijk AA, et al. Guillain‐Barré syndrome after SARS‐CoV‐2 infection in an international prospective cohort study. Brain. 2021;144:3392‐3404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Ashrafi MR, Mohammadalipoor A, Naeini AR, et al. Clinical characteristics and electrodiagnostic features of Guillain‐Barré syndrome among the pediatric population. J Child Neurol. 2020;35(7):448‐455. [DOI] [PubMed] [Google Scholar]
- 16. Tekgul H, Serdaroglu G, Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain‐Barré syndrome in children. Pediatr Neurol. 2003;28(4):295‐299. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.